Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population‐based data

• Published in: BJU international 2020-09, Vol.126 (S1), p.18-26
• Main Authors: Morton, Andrew, Williams, Michael, Perera, Marlon, Teloken, Patrick E., Donato, Peter, Ranasinghe, Sachinka, Chung, Eric, Bolton, Damien, Yaxley, John, Roberts, Matthew J.
• Format: Article
• Language: English
• Subjects: Age Factors; Aged; Australia; benign prostatic hyperplasia; Clinical trials; Cost analysis; Cystoscopy - statistics & numerical data; Drug Therapy, Combination; Dutasteride - therapeutic use; Enucleation; Genital diseases; Health Care Costs; Hospitalization - statistics & numerical data; Humans; Hyperplasia; Lasers, Solid-State - therapeutic use; Longitudinal Studies; Male; Medicare; Middle Aged; minimally invasive; Minimally Invasive Surgical Procedures - statistics & numerical data; national trends; Procedures and Techniques Utilization; Prostate; Prostatectomy - statistics & numerical data; Prostatic Hyperplasia - surgery; Prostatic Hyperplasia - therapy; Radiofrequency Ablation - statistics & numerical data; Surgery; surgical procedures; Tamsulosin - therapeutic use; transurethral resection of prostate; Transurethral Resection of Prostate - statistics & numerical data; Trends; Urological Agents - therapeutic use
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/bju.15098

Objective To examine national trends in the medical and surgical treatment of benign prostatic hyperplasia (BPH) using Australian Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) population data from 2000 to 2018. Patients and methods Annual data was extracted from the MBS, PBS and Australian Institute of Health and Welfare databases for the years 2000–2018. Population‐adjusted rates of BPH procedures and medical therapies were calculated and compared in relation to age. Cost analysis was performed to estimate financial burden due to BPH. Results Overall national hospital admissions due to BPH declined between 2000 and 2018, despite an increased proportion of admissions due to private procedures (42% vs 77%). Longitudinal trends in the medical management of BPH showed an increased prescription rate of dutasteride/tamsulosin combined therapy (111 vs 7649 per 100 000 men) and dutasteride monotherapy (149 vs 336 per 100 000 men) since their introduction to the PBS in 2011. Trends in BPH surgery showed an overall progressive increase in rate of total procedures between 2000 and 2018 (92 vs 133 per 100 000 men). Transurethral resection of the prostate (TURP) remained the most commonly performed surgical procedure, despite reduced utilisation since 2009 (118 vs 89 per 100 000 men), offset by a higher uptake of photoselective vaporisation of prostate, holmium:YAG laser enucleation of prostate, and later likely due to minimally invasive surgical therapies including prostatic urethral lift and ablative technologies (including Rezūm™). Financial burden due to BPH surgery has remained steady since 2009, whilst the burden due to medical therapy has risen sharply. Conclusion Despite reduced national BPH‐related hospitalisations, overall treatment for BPH has increased due to medical therapy and surgical alternatives to TURP. Further exploration into motivators for particular therapies and effect of medical therapy on BPH progression in clinical practice outside of clinical trials is warranted.